Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Braveheart Bio, Inc. (BRVE)

Braveheart Bio reports 52-week HRS/BHB-1893 Phase 2 extension data in oHCM at AHA meeting

Positive Impact 3 of 5 other

Braveheart Bio and Hengrui Pharma presented 52-week open-label extension data from a Phase 2 study of HRS/BHB-1893 in 42 patients with obstructive hypertrophic cardiomyopathy (oHCM) at the American Heart Association Scientific Sessions 2026. The company reported gains in exercise capacity, symptoms and LVOT gradient, and also presented diastolic function data in non-obstructive HCM. The filing contains no financial results, and the company will hold an investor event today to discuss the data and a planned fixed-dose oHCM study.

Key points

  • At Week 52, peak oxygen uptake rose a mean of 2.7 mL/kg/min and KCCQ-CSS rose a mean of 17.3 points from OLE baseline.
  • At Week 52, 79% (33/42) of patients achieved a Valsalva LVOT gradient below 30 mmHg.
  • Two patients had transient LVEF reductions below 50%, and no on-treatment severe or serious adverse events were reported.
  • Investor event and webcast scheduled for November 6, 2026, at 3:35 p.m. CT (4:35 p.m. ET).

The filing

CompanyBraveheart Bio, Inc. (BRVE)
Form8-K, current report
Filed with the SECNov 6, 2026, 3:17 PM ET
Accession number0001628280-26-071586

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:05 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.